IL-6 Inhibition in Critically Ill COVID-19 Patients Is Associated With Increased Secondary Infections

Background: Anti-inflammatory therapies such as IL-6 inhibition have been proposed for COVID-19 in a vacuum of evidence-based treatment. However, abrogating the inflammatory response in infectious diseases may impair a desired host response and pre-dispose to secondary infections. Methods: We retros...

Descripción completa

Detalles Bibliográficos
Autores principales: Kimmig, Lucas M., Wu, David, Gold, Matthew, Pettit, Natasha N., Pitrak, David, Mueller, Jeffrey, Husain, Aliya N., Mutlu, Ece A., Mutlu, Gökhan M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7655919/
https://www.ncbi.nlm.nih.gov/pubmed/33195334
http://dx.doi.org/10.3389/fmed.2020.583897

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7655919/
https://www.ncbi.nlm.nih.gov/pubmed/33195334
http://dx.doi.org/10.3389/fmed.2020.583897

Ejemplares similares